Skip to main content

Spyre Therapeutics, Inc.

SYRE
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001636282

In the last 90 days, Spyre Therapeutics, Inc. insiders filed 0 open-market purchases and 9 sales; 265 institutions reported holding it in 13F filings for Q2 2026, worth $8.52B in total; no superinvestor holds it.

13F holders, Q3 2025

Institutional positions in Spyre Therapeutics, Inc. as of Sep 30, 2025. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works

Institutional holders
137
+9 vs. Q2 2025
Shares held
64.3M
+693.4K (+1.1%) vs. Q2 2025
Total value
$1.08B
+$125.3M (+13.2%) vs. Q2 2025
New holders
22
44 more added
Sold out
13
43 more reduced

1 institution that held it in Q2 2025 haven't filed for Q3 2025 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.

Compare with Q2 2025: new holders, sold out and not filed yet

Holders and value by quarter

Institutions reporting SYRE on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.

Institutional holdersQ3 2025: 137 institutions
Q1 2021: 84 institutionsQ2 2021: 78 institutionsQ3 2021: 77 institutionsQ4 2021: 86 institutionsQ1 2022: 84 institutionsQ2 2022: 67 institutionsQ3 2022: 55 institutionsQ4 2022: 51 institutionsQ1 2023: 45 institutionsQ2 2023: 44 institutionsQ3 2023: 29 institutionsQ4 2023: 54 institutionsQ1 2024: 103 institutionsQ2 2024: 107 institutionsQ3 2024: 119 institutionsQ4 2024: 131 institutionsQ1 2025: 129 institutionsQ2 2025: 129 institutionsQ3 2025: 137 institutionsQ4 2025: 153 institutionsQ1 2026: 198 institutionsQ2 2026: 265 institutions
Value heldQ3 2025: $1.08B
Q1 2021: $328.7MQ2 2021: $285.8MQ3 2021: $322.5MQ4 2021: $189.4MQ1 2022: $95.4MQ2 2022: $24.8MQ3 2022: $23.5MQ4 2022: $19.2MQ1 2023: $12.0MQ2 2023: $31.9MQ3 2023: $43.9MQ4 2023: $601.0MQ1 2024: $1.21BQ2 2024: $1.18BQ3 2024: $1.51BQ4 2024: $1.39BQ1 2025: $1.00BQ2 2025: $952.6MQ3 2025: $1.08BQ4 2025: $2.65BQ1 2026: $4.16BQ2 2026: $8.52B
Institutions holding SYRE and their total value by quarter
QuarterHoldersValue
Q2 2026265$8.52B
Q1 2026198$4.16B
Q4 2025153$2.65B
Q3 2025137$1.08B
Q2 2025129$952.6M
Q1 2025129$1.00B
Q4 2024131$1.39B
Q3 2024119$1.51B
Q2 2024107$1.18B
Q1 2024103$1.21B
Q4 202354$601.0M
Q3 202329$43.9M
Q2 202344$31.9M
Q1 202345$12.0M
Q4 202251$19.2M
Q3 202255$23.5M
Q2 202267$24.8M
Q1 202284$95.4M
Q4 202186$189.4M
Q3 202177$322.5M
Q2 202178$285.8M
Q1 202184$328.7M

Institutions, Q3 2025

Shares, value and share of portfolio for each institution holding Spyre Therapeutics, Inc.; share changes are against Q2 2025.

Institutions holding SYRE in Q3 2025
InstitutionSharesValue% of portfolioChange in sharesAction
Victory Capital Management Inc326,081$5.47M0.00%−28,035−7.9%Reduced
Goldman Sachs Group Inc329,533$5.52M0.00%−193,883−37.0%Reduced
Morgan Stanley334,722$5.61M0.00%−336,322−50.1%Reduced
Bank of America Corp344,803$5.78M0.00%−51,548−13.0%Reduced
Siren, L.L.C.368,598$6.18M0.24%00.0%Unchanged
UBS Group AG385,589$6.46M0.00%−77,274−16.7%Reduced
Candriam Luxembourg S.C.A.404,362$6.78M0.04%+158,332+64.4%Added
Millennium Management LLC408,199$6.84M0.01%+408,199New
Charles Schwab Investment Management Inc425,345$7.13M0.00%+6,842+1.6%Added
Northern Trust Corp442,036$7.41M0.00%+5,089+1.2%Added
Blackstone Group Inc.500,998$8.40M0.04%+11,750+2.4%Added
Emerald Advisers, LLC548,712$9.20M0.29%−17,151−3.0%Reduced
Deerfield Management Company, L.P. (Series C)613,665$10.3M0.16%00.0%Unchanged
Price T Rowe Associates Inc620,620$10.4M0.00%−309,861−33.3%Reduced
Polar Capital Holdings Plc788,788$13.2M0.06%+43,788+5.9%Added
Franklin Resources Inc795,275$13.3M0.00%00.0%Unchanged
Baker Bros. Advisors LP1,000,000$16.8M0.12%+373,297+59.6%Added
Pictet Asset Management Holding SA1,036,218$17.4M0.02%−43,225−4.0%Reduced
TCG Crossover Management, LLC1,100,582$18.4M0.91%+1,100,582New
Geode Capital Management, LLC1,225,153$20.5M0.00%−2,079−0.2%Reduced
Perceptive Advisors LLC1,229,445$20.6M0.60%−300,000−19.6%Reduced
Jefferies Financial Group Inc.1,388,854$23.3M0.21%00.0%Unchanged
Affinity Asset Advisors, LLC1,419,299$23.8M2.21%+812,621+133.9%Added
Paradigm Biocapital Advisors LP1,467,266$24.6M0.73%−403,179−21.6%Reduced
Wellington Management Group LLP1,640,312$27.5M0.00%+126,834+8.4%Added
State Street Corp1,785,206$29.9M0.00%+189,915+11.9%Added
Commodore Capital LP1,988,084$33.3M1.63%00.0%Unchanged
Driehaus Capital Management LLC2,060,375$34.5M0.25%−25,215−1.2%Reduced
Capital International Investors2,392,541$40.1M0.01%00.0%Unchanged
Braidwell LP2,578,404$43.2M1.28%00.0%Unchanged
VR Adviser, LLC2,685,448$45.0M2.53%00.0%Unchanged
Vanguard Group Inc3,050,730$51.1M0.00%−15,856−0.5%Reduced
Tang Capital Management LLC3,200,000$53.6M2.06%00.0%Unchanged
RTW Investments, LP3,621,996$60.7M0.75%00.0%Unchanged
BlackRock, Inc.3,982,744$66.8M0.00%−24,552−0.6%Reduced
Fairmount Funds Management LLC4,018,101$67.3M6.06%00.0%Unchanged
FMR LLC9,060,144$151.8M0.01%+7,110+0.1%Added
Adage Capital Partners GP, L.L.C.0$00.00%−610,200−100.0%Sold out
Deep Track Capital, LP0$00.00%−219,015−100.0%Sold out
Capitolis Liquid Global Markets LLC0$00.00%−183,000−100.0%Sold out
Foresite Capital Management VI LLC0$00.00%−70,000−100.0%Sold out
Susquehanna International Group, LLP0$00.00%−59,816−100.0%Sold out
Renaissance Technologies LLC0$00.00%−30,936−100.0%Sold out
Natixis0$00.00%−20,040−100.0%Sold out
Voya Investment Management LLC0$00.00%−13,589−100.0%Sold out
Man Group plc0$00.00%−10,843−100.0%Sold out
Skopos Labs, Inc.0$00.00%−520−100.0%Sold out
Simplex Trading, LLC0$00.00%−145−100.0%Sold out
Caitong International Asset Management Co., Ltd0$00.00%−102−100.0%Sold out
Raymond James Financial Inc0$00.00%−16−100.0%Sold out
NBW Capital LLC––––Not filed